Since ALDH has been shown to confer cellular resistance to a variety of cytotoxic drugs used for breast cancer, such as cyclophosphamide and its active derivative [114,115], doxorubicin [116] and cisplatin [116,117], this offers a potential mechanism for how RhoC mediates chemoresistance in breast cancer cells. Here, RHOC is linked to breast carcinoma.